Description The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies. This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology and diagnostic...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
Description
The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies.
This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2003 to early 2010.
The report provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains over 1000 links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of manufacturing and supply dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply as well as a discussion on the merits of each type of deal.
Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure manufacturing/supply deals and multicomponent deals where manufacturing/supply forms a part.
Chapters 5 and 6 provide a review of the leading manufacturing/supply deals since 2000, respectively. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of manufacturing and supply contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapters 8 and 9 provide a comprehensive listing of all manufacturing and supply agreement contracts since 2003 available in the public domain, respectively. Each chapter is organized by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.
Key benefits
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following Key benefits:
* In-depth understanding of manufacturing and supply deal trends since 2000
* Analysis of the structure of manufacturing and supply agreements with numerous real life case studies
* Comprehensive access to over 1000 actual manufacturing and supply contracts entered into by the world’s biopharma companies
* Detailed access to actual manufacturing and supply contracts enter into by the leading fifty bigpharma companies
* Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
* Understand the key deal terms companies have agreed in previous deals
* Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the manufacturing and supply trends and structure of deals entered into by leading biopharma companies worldwide.
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
* Trends in manufacturing and supply dealmaking in the biopharma industry since 2000
* Analysis of manufacturing and supply deal structure
* Case studies of real-life manufacturing and supply deals
* Access to over 1000 manufacturing and supply contract documents
* The leading manufacturing and supply deals by value since 2000
* Most active manufacturing and supply dealmakers since 2000
* The leading manufacturing and supply partnering resources
In Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available contracts are listed by:
* Company A-Z
* Headline value
* Stage of development at signing
* Therapeutic area
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Diagnostics Industry
Table of Contents
Number of pages: 589
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in manufacturing and supply dealmaking
* 2.1. Introduction
* 2.2. Difference between manufacturing and supply deals
* 2.3. Trends in manufacturing deals since 2000
* 2.4. Trends in supply deals since 2000
* 2.4.1. When supply can be useful
* 2.5. Pure deals and multi-component deals
* 2.5.1. Attributes of pure manufacturing and supply deals
* 2.5.2. Attributes of manufacturing and supply in multi-component deals
* 2.6. Reasons for including manufacturing and supply options in a multicomponent deal
* 2.7. The future of manufacture and supply as part of multicomponent deals
Chapter 3 – Overview of manufacturing deal structure
* 3.1. Introduction
* 3.2. Pure versus multi-component manufacturing deals
* 3.3. Pure manufacturing agreement structure
* 3.3.1. Example manufacturing agreements
* 3.3.1.a. Case study 1: Lonza – Tercica – May 2007
* 3.3.1.b. Case study 2: Cardinal Health – Targanta – March 2007
* 3.4. Manufacturing rights as part of a wider alliance agreement
* 3.4.1. Example multicomponent manufacturing clauses
* 3.4.1.a. Case study 3: Janssen – Vertex – June 2006
* 3.4.1.b. Case study 4: Ipsen – Medicis – March 2006
Chapter 4 – Overview of supply deal structure
* 4.1. Introduction
* 4.2. Supply agreement structure
* 4.2.1. Example supply agreements
* 4.2.1.a. Case study 5: Novartis – Unigene – January 2007
* 4.2.1.b. Case study 6: Watson – Savient – June 2006
* 4.3. Supply rights as part of a wider alliance agreement
* 4.3.1. Example co-marketing right clauses
* 4.3.1.a. Case study 7: Shionogi – BioCryst – February 2007
* 4.3.1.b. Case study 8: Schering Plough - Xoma – May 2006
Chapter 5 – Leading manufacturing deals
* 5.1. Introduction
* 5.2. Top manufacturing deals by value
* 5.3. Top pure manufacturing deals
* 5.4. Top manufacturing deals signed by bigpharma
* 5.5. Most active manufacturing dealmakers
* 5.6. Bigpharma manufacturing deal activity
Chapter 6 – Leading supply deals
* 6.1. Introduction
* 6.2. Top supply deals by value
* 6.3. Top pure supply deals
* 6.4. Top supply deals signed by bigpharma
* 6.5. Most active supply dealmakers
* 6.6. Bigpharma supply deal activity
Chapter 7 – Bigpharma manufacturing and supply agreements
* 7.1. Introduction
* 7.2. How to use manufacturing and supply agreements
* 7.3. Company manufacturing and supply agreement listings
* Abbott
* Actavis
* Akzo Nobel
* Alcon Labs
* Allergan
* Altana
* Amgen
* Astellas
* AstraZeneca
* Baxter International
* Bayer
* Bayer Schering Pharma AG
* Biogen Idec
* Boehringer Ingelheim
* Bristol-Myers Squibb
* Cephalon
* Chugai
* CSL
* Dainippon Sumitomo
* Eisai
* Eli Lilly
* Forest Laboratories
* Genentech
* Genzyme
* Gilead Sciences
* GlaxoSmithKline
* Johnson & Johnson
* King
* Lundbeck
* Menarini
* Merck & Co
* Merck KGaA
* Mitsubishi
* Novartis AG
* Novo Nordisk
* Nycomed Pharma
* Otsuka
* Pfizer
* Procter & Gamble
* Roche
* Sanofi-Aventis
* Schering Plough
* Serono
* Shionogi Seiyaku
* Shire
* Solvay
* Takeda
* Tanabe Seiyaku
* TAP Pharmaceuticals
* Teva
* UCB
* Watson
* Wyeth
Chapter 8 – Manufacturing agreement directory 2003-2010
* 8.1. Introduction
* 8.2. Company A-Z
* 8.3. By therapy area
* Accident/Hospital/Trauma
* Blood/Lymphatic System
* Cardiovascular
* Central nervous System
* Dermatology
* Gastrointestinal
* Genitourinary
* Autoimmune/Inflammatory
* Infection
* Metabolism
* Musculoskeletal
* Oncology
* Respiratory
* Sensory Organ / Oral Health
* Drug Delivery
* OTC
* 8.4. By stage of development at signing
* Discovery
* Preclinical
* Phase I
* Phase II
* Phase III
* Registration
* Formulation
* Market
Chapter 9 – Supply agreement directory 2003-2010
* 9.1. Introduction
* 9.2. Company A-Z
* 9.3. By therapy area
* Accident/Hospital/Trauma
* Agriculture
* Blood/Lymphatic System
* Cardiovascular
* Central nervous System
* Dermatology
* Gastrointestinal
* Genetic
* Genitourinary
* Autoimmune/Inflammatory
* Infection
* Metabolism
* Musculoskeletal
* Oncology
* Respiratory
* Sensory Organ / Oral Health
* Over the Counter
* 9.4. By stage of development at signing
* Discovery
* Preclinical
* Phase I
* Phase II
* Phase III
* Registration
* Formulation
* Market
Appendices
* Appendix 1 – Manufacturing and supply references
* Appendix 2 – Resources
* Appendix 3 – Deal type definitions
* Appendix 3 – Deal type definitions
* Appendix 4 – Example manufacturing document
* Appendix 5 – Example supply document
* About CurrentPartnering
* Recent report titles from CurrentPartnering
* Order Form – Reports
* Order form – Company Dealmaking Profiles
TABLE OF FIGURES
* Figure 1: Definition of manufacturing and supply
* Figure 2: Types of manufacturing agreement
* Figure 3: Trends in manufacturing deal announcements, 2000-2009
* Figure 4: Manufacturing deals signed at what phase of development, 2000-2009
* Figure 5: Trends in supply deal announcements, 2000-2009
* Figure 6: Supply deals signed at what phase of development, 2000-2009
* Figure 7: Situations where supply deals can prove useful
* Figure 8: Pure versus multi-component manufacturing deal announcements, 2000-2009
* Figure 9: Stage of development at which pure and multi-component manufacturing deals are announced 2000-2009
* Figure 10: Pure versus multi-component supply deal announcements, 2000-2009
* Figure 11: Stage of development at which pure and multi-component supply deals are announced 2000-2009
* Figure 14: Components of the manufacturing deal structure
* Figure 15: Components of the supply deal structure
* Figure 16: Top manufacturing deals by value since 2003
* Figure 17: Top pure manufacturing deals by value since 2003
* Figure 18: Top manufacturing deals signed by bigpharma value since 2003
* Figure 19: Most active manufacturing dealmakers 2003-7
* Figure 20: Bigpharma – top 50 – manufacturing deals since 2003
* Figure 21: Top supply deals by value since 2003
* Figure 22: Top pure supply deals by value since 2003
* Figure 23: Bigpharma – top 50 – supply deals since 2003
* Figure 24: Most active supply dealmakers 2003-2009
* Figure 25: Bigpharma – top 50 – supply deals since 2003
* Figure 26: Online partnering resources
* Figure 27: Deal type definitions
* Figure 28: Manufacturing agreement between Tercica and Lonza, May 2007
* Figure 29: Supply agreement between Novartis and Unigene, January 2007
